Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice
- 1 July 1993
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 71 (1-3) , 189-196
- https://doi.org/10.1016/0304-3835(93)90115-p
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Cancer statistics, 1992CA: A Cancer Journal for Clinicians, 1992
- IGF-I and IGF-Binding Proteins: Stimulatory and Inhibitory Factors Secreted by Human Prostatic Adenocarcinoma CellsGrowth Factors, 1991
- Production of epidermal growth factor and transforming growth factor‐α by the androgen‐responsive LNCaP human prostate cancer cell lineThe Prostate, 1990
- Role of transforming growth factor -α in human prostate cancer cell growthThe Prostate, 1989
- Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostateThe Prostate, 1989
- Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell lineThe Prostate, 1989
- Growth factor involvement and oncogene expression in prostatic tumoursJournal of Steroid Biochemistry, 1988
- Treatment of Advanced Prostatic CancerUrologic Clinics of North America, 1987
- The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancerThe Prostate, 1984
- Physiologic Basis for Hormonal Therapy in Carcinoma of the ProstateUrologic Clinics of North America, 1975